Aura Biosciences, Inc. (NASDAQ:AURA) Sees Large Decrease in Short Interest

Aura Biosciences, Inc. (NASDAQ:AURA) saw a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 1,120,000 shares, a decline of 13.2% from the February 13th total of 1,290,000 shares. Approximately 2.5% of the company’s shares are short sold. Based on an average daily volume of 158,600 shares, the days-to-cover ratio is currently 7.1 days.

Wall Street Analysts Forecast Growth

Separately, Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Stock Performance

Shares of AURA stock opened at $7.42 on Friday. Aura Biosciences has a 52-week low of $6.63 and a 52-week high of $12.38. The company has a 50-day simple moving average of $7.66 and a two-hundred day simple moving average of $8.65. The company has a market capitalization of $370.64 million, a price-to-earnings ratio of -4.29 and a beta of 0.30.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the transaction, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 23,045 shares of company stock valued at $177,242 over the last 90 days. 5.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new position in Aura Biosciences in the 4th quarter worth approximately $50,000. China Universal Asset Management Co. Ltd. purchased a new stake in Aura Biosciences in the 4th quarter worth approximately $87,000. ProShare Advisors LLC purchased a new stake in Aura Biosciences in the 4th quarter worth approximately $127,000. Harvest Investment Services LLC purchased a new stake in Aura Biosciences in the 4th quarter worth approximately $133,000. Finally, AlphaQuest LLC purchased a new stake in Aura Biosciences in the 4th quarter worth approximately $136,000. 96.75% of the stock is owned by institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.